Evidence map›Paper›PMID 42108428›Full record

ArticleCancer medicine2026

Partnership Driving Impact: An Integrated Women-Centric Model to Improve Early Detection and Treatment of Cervical and Breast Cancer in Ghana and India.

Mary Efua Commeh, Nuzhat Husain, Christabel Boaduwaa Afrane, Mavis Apatu, Amos Asiedu, Margaret Mary Bertram, Parag Bhamare, Nimrit Kaur, John Kafui Klu, Christina Lorenz and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mary Efua CommehGhana Health Service, Accra, Ghana.
Nuzhat HusainDepartment of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India.
Christabel Boaduwaa AfraneJhpiego, Johns Hopkins University, Accra, Ghana.
Mavis ApatuJhpiego, Johns Hopkins University, Accra, Ghana.
Amos AsieduJhpiego, Johns Hopkins University, Accra, Ghana.
Margaret Mary BertramJhpiego, John Hopkins University, Baltimore, Maryland, USA.
Parag BhamareJhpiego, John Hopkins University, Baltimore, Maryland, USA.
Nimrit KaurJhpiego, John Hopkins University, Baltimore, Maryland, USA.
John Kafui KluRoche Products Ltd, Accra, Ghana.
Christina LorenzF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Maura McCarthyJhpiego, John Hopkins University, Baltimore, Maryland, USA.
Louisa PrekoRoche Products Ltd, Accra, Ghana.
Stephanie SassmanGenentech, Inc., South San Francisco, California, USA.
Blessing TawariF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Joni ZurawinskiRoche Diagnostics Ltd, Rotkreuz, Switzerland.
Keith DawsonGenentech, Inc., South San Francisco, California, USA.ORCID https://orcid.org/0009-0007-8683-9307

Funding

F. Hoffmann-La Roche, Ltd.Genentech, Inc
6 · The paper itself

Abstract

introductionCervical and breast cancer are the leading causes of women's cancer mortality in Ghana and India. Using an integrated, scalable approach of screening, diagnosis, and treatment, 2 real-world programs were independently designed and conducted in Ghana and India. Each program was adapted to the local healthcare infrastructure to increase screening and management of breast and cervical cancers.

methodsGovernment, healthcare, industry, non-governmental organization, and community leader partnerships in Ghana and India created a comprehensive patient engagement framework. Cascade training in cervical and breast cancer for healthcare workers, cancer awareness community outreach, screening, and follow-up for women were instituted. Patient navigators and accredited social health activists supported patients throughout the program. Human papillomavirus (HPV) DNA testing and HPV DNA self-sample collection were introduced.

resultsIn the Bekwai municipality of Ghana, 20 facilities participated in the screening program. Sixteen trainers and 70 providers were trained. Of 5730 women screened for breast cancer; 100% of 113 with confirmed breast abnormalities had diagnostic services and treatment if necessary. For cervical cancer screening, 4997 women provided samples (80% self-collected); 811 were HPV-positive, 609 (75%) returned for further assessment, and of those, 100% were treated. In Amethi, India, 19 facilities participated. Forty trainers and providers were trained. Collectively, 4505 women were screened for breast cancer; 28/123 with abnormalities (23%) were referred for further management. Of 10,141 women who provided cervical samples (75% self-collected), 370 were HPV-positive, and 193/370 women (52%) returned for treatment or referral to tertiary centers.

conclusionsEstablishing multiple-stakeholder partnerships resulted in cervical and breast cancer screening programs that were successfully implemented into routine clinical service in diverse environments and resulted in large numbers of women receiving cancer screening and treatment.

Indexed as

Breast NeoplasmsEarly Detection of CancerUterine Cervical NeoplasmsAdultFemaleGhanaHuman Papillomavirus VirusesHumansIndiaMass ScreeningMiddle AgedPapillomavirus Infectionsbreast cancercervical cancerHPV self‐collectionscreening

Identifiers

PMID42108428
PMCPMC13158161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.